Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

NCRI 2013 /
Molecular imaging using PET-CT and personalised therapy with neuroendocrine tumours

3rd - 6th Nov 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.11.13
Views: 3250

Dr Harshad Kulkarni - Zentralklinik, Bad Berka, Germany

Dr Harshad Kulkarni talks to ecancer at the 2013 NCRI Cancer Conference in Liverpool about PET/CT on neuroendocrine tumours.

A German multi-institutional registry study found that this is an effective therapy for patients with G1-2 neuroendocrine tumours with a survival advantage of several years compared to other therapies and only minor side effects.

The concept of theranostics has now been translated to other malignancies such as prostate cancer.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation